What is Medical Imaging AI?
TL;DR
AI that analyzes CT / MRI / X-ray / pathology images to detect disease. Aidoc / Viz.ai / PathAI deliver -50% diagnosis time, -40% misses, 700+ US FDA clearances. $50B market by 2030 (35% CAGR).
Medical Imaging AI: Definition & Explanation
Medical Imaging AI uses Convolutional Neural Networks (CNN) / Vision Transformers (ViT) / Foundation Models to analyze CT / MRI / X-ray / ultrasound / pathology / fundus / skin images and detect strokes, pulmonary embolism, cancer, myocardial infarction, diabetic retinopathy, and more. US FDA Class II/III medical-device clearance is required; cumulative 2024 clearances exceed 700 (60% radiology / 15% cardiovascular). Market: $15B in 2024 - $50B by 2030 (35% CAGR).\n\nKey platforms: (1) Aidoc (Israel $240M, 1,500 US hospitals, 12 FDA clearances, CT stroke / PE / cervical fracture / brain hemorrhage, Nvidia / General Catalyst backed, 20M cases), (2) Viz.ai (US $252M, #1 FDA-cleared stroke LVO detection, Mount Sinai / Mayo, -39 min Door-to-Needle), (3) PathAI (US $255M, pathology AI standard, Roche / BMS / Bayer drug discovery, Harvard Medical School origin), (4) Tempus AI (NASDAQ:TEM $10B mkt cap, cancer genomics + imaging + EHR, AI Precision Oncology, founded by Eric Lefkofsky), (5) Annalise.ai (Australia $70M, chest X-ray 124 findings, Harrison.ai sister company, UK NHS), (6) Cleerly (US $381M, coronary CT AI, Mayo / Cleveland Clinic), (7) RapidAI (US $75M, stroke Penumbra / CTA, Stanford origin, 2,000 US hospitals), (8) Paige.AI (US $220M, #1 FDA-cleared pathology AI for prostate cancer, MSK origin), (9) Lunit (Korea KOSDAQ $4B, chest X-ray / mammography, GE HealthCare partnership), (10) Qure.ai / Butterfly Network / iCAD (WHO / J&J acquisition / mammography 3,000 US sites).\n\nUse cases: (I) stroke emergency diagnosis (Viz.ai / Aidoc / RapidAI, CT 5-min triage, 800K strokes/yr saved), (II) pulmonary embolism / aortic dissection CT (Aidoc, -40% misses, Mount Sinai 30% earlier detection), (III) chest X-ray AI (Annalise.ai / Lunit / Qure.ai, 124 findings, TB / lung cancer / COVID, UK NHS / WHO), (IV) mammography AI (Lunit / iCAD / Hologic, 3,000 US sites, -30% misses), (V) pathology AI (PathAI / Paige.AI, prostate / breast / colorectal, Roche / BMS new drugs), (VI) coronary CT AI (Cleerly / HeartFlow, heart-attack prevention, CMS reimbursement), (VII) fundus AI for diabetic retinopathy (IDx-DR FDA first clearance 2018, Walmart / CVS), (VIII) skin AI (SkinVision / Skinive / DermAssist, 2M downloads), (IX) portable ultrasound AI (Butterfly Network J&J acquisition, $2K, AI guidance), (X) cancer genomics + imaging precision oncology (Tempus AI, 3,000 US hospitals).\n\nOutcomes: Aidoc 1,500 US hospitals / 20M cases / -50% diagnosis time, Viz.ai 5M scans / -39 min Door-to-Needle, PathAI 5,000 US pathologists / Roche partnership, Tempus AI NASDAQ-listed $10B mkt cap, Annalise.ai 124 findings / UK NHS, Lunit KOSDAQ $4B, 700+ FDA clearances, -40% missed diagnoses.\n\nRisks: (★) FDA clearance / regulatory risk (Class II/III required, uncleared AI is research-use only; verify FDA 510(k) / CE Mark / PMDA), (★) false positives / negatives leading to malpractice (Lunit false-negative lawsuits, Aidoc false positives, AI as 2nd reader with human final call), (★) HIPAA / GDPR data leakage ($1M HIPAA fines, Viz.ai breach allegations, BAA / SOC2 / local processing preferred), (★) radiologist pushback / job-displacement fears (Hinton 2016, AI as co-pilot with +30% productivity, ACR / ESR guidelines), (★) reimbursement / monetization difficulty (no US CMS code initially, Value-Based Care, ROI from reduced litigation).\n\nTrends for 2026: (★) FDA AI/ML clearances cross 700 (2024, 60% radiology / 15% cardiovascular), (★) Foundation Models for healthcare (Google Med-PaLM 2 / Microsoft RAD-DINO / Meta DINOv2-Medical, +20% diagnostic accuracy), (★) multimodal integration (imaging + genomics + EHR, Tempus AI pioneer, precision oncology), (★) AI drug discovery (PathAI / Tempus / Recursion, Roche / BMS / Bayer partnerships, AlphaFold linkage, -50% drug-development time), (★) EU AI Act 2026 enforcement (medical AI high-risk, CE Mark MDR, $30M fines), (★) Japan market (PMDA 50+ AI clearances, 2024 reimbursement bonus for AI imaging diagnostics, ELPIXEL EIRL / AI Medical Service, ¥300B by 2030), (★) generative AI radiology reports (Microsoft Rad-DINO / Nuance DAX, -50% radiologist time).